Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Financing Activities (2017 - 2025)

Aclaris Therapeutics has reported Cash from Financing Activities over the past 9 years, most recently at -$2.5 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$2.5 million for Q4 2025, down 103.4% from a year ago — trailing twelve months through Dec 2025 was -$5.9 million (down 107.86% YoY), and the annual figure for FY2025 was -$5.9 million, down 107.86%.
  • Cash from Financing Activities for Q4 2025 was -$2.5 million at Aclaris Therapeutics, up from -$3.0 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ACRS hit a ceiling of $135.9 million in Q2 2021 and a floor of -$11.6 million in Q3 2021.
  • Median Cash from Financing Activities over the past 5 years was -$5500.0 (2021), compared with a mean of $20.4 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 152104.08% in 2024 and later plummeted 13936.36% in 2025.
  • Aclaris Therapeutics' Cash from Financing Activities stood at -$2000.0 in 2021, then skyrocketed by 1950.0% to $37000.0 in 2022, then skyrocketed by 32.43% to $49000.0 in 2023, then soared by 152104.08% to $74.6 million in 2024, then tumbled by 103.4% to -$2.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$2.5 million (Q4 2025), -$3.0 million (Q3 2025), and -$9000.0 (Q2 2025) per Business Quant data.